PreTect SEE is ideal as a quality control test for NILM cytology. It is an assay for the qualitative detection of the presence of Human Papillomavirus, HPV, E6/E7 oncogene mRNA from carcinogenic HPV types 16, 18 and 45.
PreTect SEE shows high clinical specificity, supported by a low positive rate in the general population.
This CE-IVD kit identify women that have carcinogenic expression of high-risk HPV types that may induce cervical cancer. Co-testing with PreTect SEE and Cytology will therefore improve the existing screening program sensitivity without an excessive follow-up workload.
With its high capacity and low cost the test is also ideal as stand-alone test in low-income countries.
Qualitative detection of E6/E7 mRNA expression from HPV 16, 18, 45
Intrinsic sample control ensuring sample adequacy
High clinical specificity minimising unnecessary interventions
High PPV for CIN2+
Enhanches identification of cervical adenocarcinoma
Low positivity rate in general population
|Individual HPV genotyping||E6/E7 mRNA HPV 16, 18 and 45|
|Intrinsic Sample Control (ISC):||Targeting mRNA from housekeeping gene|
|Sample type:||Cervical samples|
|Preservatives:||PreTect TM (PreTect AS)|
|SurePath (BD Diagnostics)|
|Input-material:||Isolated Nucleic Acid (DNA/RNA)*|
|Technology:||Real time NASBA|
|Isothermal amplification (41°C)|
|Four specific molecular beacons|
|Format:||96-well PCR plate|
|Pre-filled with reagents|
|Assay time:||~ 150 minutes|
|Instrumentation:||Fluorescence reader /|